CRIS Stock Forecast: Curis, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.43

The median 12-month analyst price target for Curis, Inc. is $20. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 35 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$4.5M
Ticker Nerd rank
35/ 100
Median analyst target
$20
Analysts covering
4
Revenue$0.0−100.0% y/y
Operating income−$9.9M
Net income−$8.6M
Free cash flow−$9.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Curis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
35/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
59
Issuance
56
Accruals
55
Volatility
41
Quality
32
Growth
27
Momentum
22
Value
12

Revisions (59): Analysts have, on balance, been raising their forecasts.

Value (12): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CRIS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRIS, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$6
Low
$20
Median
$65
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
13 Nov 2026HC Wainwright & Co.MaintainsBuy$43 → $6.00
17 Aug 2026HC Wainwright & Co.ReiteratesBuy$43
24 July 2026HC Wainwright & Co.MaintainsBuy$17 → $43
20 Mar 2026HC Wainwright & Co.ReiteratesBuy$17
19 May 2025HC Wainwright & Co.AssumesBuy$17
31 Mar 2025HC Wainwright & Co.MaintainsBuy—
10 Dec 2024HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
1 Nov 2024HC Wainwright & Co.MaintainsBuy—
27 Sept 2024HC Wainwright & Co.ReiteratesBuy$26
1 Aug 2024HC Wainwright & Co.ReiteratesBuy—
15 May 2024Cantor FitzgeraldReiteratesOverweight—
15 May 2024HC Wainwright & Co.ReiteratesBuy—
15 May 2024Truist SecuritiesMaintainsBuy—
8 May 2024HC Wainwright & Co.ReiteratesBuy—
9 Feb 2024HC Wainwright & Co.MaintainsBuy—
17 Nov 2023Truist SecuritiesInitiatesBuy—
29 Sept 2023HC Wainwright & Co.ReiteratesBuy$6.00 → $51
25 Sept 2023HC Wainwright & Co.ReiteratesBuy$6.00
7 Sept 2023Cantor FitzgeraldReiteratesOverweight$3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CRIS.

Market Radar

This page is one stock. Monday covers all of them.

CRIS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

CRIS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 97% of US stocks

Price / sales
3.8×

Cheaper than 28% of US stocks

Price / book
0.7×

Cheaper than 80% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−138.8%

Higher than 10% of US stocks

Return on assets
−101.7%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Curis, Inc. has a market value of $4.5M and an enterprise value of $191K.

  • Revenue in the twelve months to 30 June 2026: $4.3M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$21.2M, a −490.3% net margin.

  • Diluted earnings per share, trailing twelve months: −$14.22.

  • Free cash flow in the twelve months to 30 June 2026: −$30.6M.

  • Shares outstanding: 1.9M.

  • Trailing P/E: 0.0×.

  • Curis, Inc. employs 20 people — $216K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

CRIS and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRISCuris, Inc.$4.5M35
LTRNLantern Pharma, Inc.$3.9M24
PCSAProcessa Pharmaceuticals, Inc.$4.4M21
ALZNAlzamend Neuro, Inc.$3.7M27
AIMAIM ImmunoTech, Inc.$4.5M33
SILOSilo Pharma, Inc.$3.6M16
SNTISenti Biosciences Holdings, Inc.$4.6M33

Take a look at CRIS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Curis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CRIS

What is the CRIS stock price forecast for 2026-2027?

The median 12-month analyst price target for Curis, Inc. is $20, with estimates ranging from $6 to $65. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRIS stock a buy right now?

Of the 4 analysts covering Curis, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Curis, Inc. 35 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRIS?

As at 21 Nov 2026, Curis, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (59 of 100).

Will CRIS stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $20, and Ticker Nerd's factor model ranks Curis, Inc. 35 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRIS stock forecast for 2030?

No analyst covering Curis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRIS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $65 over the next 12 months.

What does Curis, Inc. do?

Curis Inc. is a biotechnology company focused on developing and commercializing innovative therapeutics for cancer treatment. The company’s current portfolio centers on targeted drug candidates designed to address specific cancer-driving pathways and patient groups, with programs spanning hematologic malignancies and solid tumors.

Company

About Curis, Inc.

Curis Inc. is a biotechnology company focused on developing and commercializing innovative therapeutics for cancer treatment. The company’s current portfolio centers on targeted drug candidates designed to address specific cancer-driving pathways and patient groups, with programs spanning hematologic malignancies and solid tumors. Its work includes small-molecule and antibody-based therapies, as well as marketed or advanced-stage assets in oncology and related disease areas. Curis also collaborates with research and development partners to advance its pipeline and expand the clinical profile of its programs. Based in Lexington, Massachusetts, Curis Inc. plays a specialized role in the oncology drug development market, where it contributes to the discovery and testing of precision medicines intended for use in areas with significant unmet medical need.

CEO Mr. James E. Dentzer · 20 employees · United States · https://www.curis.com